1-s2.0-S2329050121001728-main.pdf (3.23 MB)
Download file

Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device

Download (3.23 MB)
journal contribution
posted on 08.11.2021, 11:17 by Cristina Olgasi, Chiara Borsotti, Simone Merlin, Thorsten Bergmann, Patrick Bittorf, Adeolu Badi Adewoye, Nicholas Wragg, Kelcey Patterson, Andrea Calabria, Fabrizio Benedicenti, Alessia Cucci, Alessandra Borchiellini, Berardino Pollio, Eugenio Montini, Delfina M Mazzuca, Martin Zierau, Alexandra StolzingAlexandra Stolzing, Philip M Toleikis, Joris Braspenning, Antonia Follenzi
Hemophilia A (HA) is a rare bleeding disorder caused by deficiency/dysfunction of the FVIII protein. As current therapies based on frequent FVIII infusions are not a definitive cure, long-term expression of FVIII in endothelial cells through lentiviral vector (LV)-mediated gene transfer holds the promise of a one-time treatment. Thus, here we sought to determine whether LV-corrected blood outgrowth endothelial cells (BOECs) implanted through a prevascularized medical device (Cell Pouch™) would rescue the bleeding phenotype of HA mice. To this end, BOECs from HA patients and healthy donors were isolated, expanded and transduced with an LV carrying FVIII driven by an endothelial-specific promoter employing GMP-like procedures. FVIII-corrected HA-BOECs were either directly transplanted into the peritoneal cavity or injected into a Cell Pouch™ implanted subcutaneously in NSG-HA mice. In both cases, FVIII secretion sufficient to improve the mouse bleeding phenotype. Indeed, FVIII-corrected HA-BOECs reached a relatively short-term clinically relevant engraftment being detected up to 16 weeks after transplantation, and their genomic integration profile did not show enrichment for oncogenes, confirming the process safety. Overall, this is the first pre-clinical study showing the safety and feasibility of transplantation of GMP-like produced LV-corrected BOECs within an implantable device for the long-term treatment of HA.

Funding

European Union's Horizon 2020 research and innovation program under grant agreement HemAcure No. 667421

Telethon grant No. GGP19201

Vanguard grant No. 874700

Università del Piemonte Orientale (FAR 2017)

Fondazione Carliplo grant No 2018-0253

Italian Minister of Health “Ricerca 523 Sanitaria finalizzata” Giovani Ricercatori Grant No 2018-12366399

History

School

  • Mechanical, Electrical and Manufacturing Engineering

Published in

Molecular Therapy - Methods & Clinical Development

Volume

23

Pages

551-566

Publisher

Elsevier BV

Version

VoR (Version of Record)

Rights holder

© The Authors

Publisher statement

This is an Open Access Article. It is published by Elsevier under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). Full details of this licence are available at: https://creativecommons.org/licenses/by-nc-nd/4.0/

Acceptance date

29/10/2021

Publication date

2021-11-03

Copyright date

2021

ISSN

2329-0501

Language

en

Depositor

Prof Alexandra Stolzing. Deposit date: 5 November 2021

Usage metrics

Categories

Keywords

Exports